We are excited to announce that we have launched the generic version of Precedex® (Dexmedetomidine Hydrochloride Injection) in partnership with Sagent Pharmaceuticals. The product is available in 200 mcg per 50 mL and 400 mcg per 100 mL glass bottles. This launch addresses the ongoing shortage of Dexmedetomidine Hydrochloride Injection in the U.S., providing a crucial...
And another achievement, enhancing medicines accessibility! A.forall, is proud to announce that its U.S. partner, Woodward Pharma Services LLC, has just commercialized its Supplemental Abbreviated New Drug Application (sANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Sodium Acetate Injection 4 mEq/mL marketed by Fresenius Kabi USA LLC. Sodium Acetate...
We are proud to announce that Milla Pharmaceuticals Inc., an A.forall company, in partnership with Acella Pharmaceuticals LLC, has successfully commercialized its Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Mestinon® (Pyridostigmine Bromide Syrup) 60 mg/5mL. Pyridostigmine Bromide Syrup is indicated for the symptomatic treatment of...
The Alter Pharma Group is excited to announce its rebranding, uniting all its brands and businesses. We were already sharing One Mission, and now we also share one brand, one name: A.forall. This change represents an important milestone in A.forall’s pursuit of a world where patients can access high-quality, safe and innovative medicines at an affordable...
We are proud to announce that it has received FDA approval for its generic version of Precedex®, Dexmedetomidine Hydrochloride Injection. The product is set to launch very soon. Dexmedetomidine Hydrochloride Injection plays a vital role in sedating patients who are initially intubated and mechanically ventilated during intensive care treatment. Administered through continuous infusion for a...
Milla Pharmaceuticals successfully partnered with Athenex Pharmaceutical Division (APD) to release a generic version of Magnesium Sulfate in Water for Injection. The U.S. Food and Drug Administration (FDA) has approved the abbreviated new drug application (ANDA) for Magnesium Sulfate Injection, which is currently on the ASHP Drug Shortages List . The product is intended to...
Milla Pharmaceuticals Inc., announces U.S. Food and Drug Administration (FDA) has granted approval to the Company’s Abbreviated New Drug Application (ANDA) for a generic version of Mestinon® (Pyridostigmine Bromide Syrup) 60 mg/5mL. Pyridostigmine Bromide Syrup is indicated for symptomatic treatment of myasthenia gravis. Myasthenia gravis is a neuromuscular disorder primarily characterized by muscle weakness and...
The Alter Pharma Group is proud to announce having acquired EcoPharmaSupply (EPS). EPS is a Belgian pharmaceutical services and products company, distributor and partner of choice for several pharmaceutical brands on the Benelux market including prescription drugs, medical devices, OTC pharmaceuticals and consumer health products. The investment will allow Alter Pharma to enhance its services and product offering further leveraging its regulatory compliance...
Milla Pharmaceuticals, a subsidiary of the Alter Pharma Group, announced that it has received abbreviated new drug application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for its generic version of Magnesium Sulfate in Water for Injection, 2 g/50 mL (40 mg/mL), 4 g/100 mL (40 mg/mL), and 4 g/50 mL (80 mg/mL),...
– Company granted 180-days of exclusivity under FDA Competitive Generic Therapy approval pathway – Milla Pharmaceuticals, a subsidiary of the Alter Pharma Group, announced that it has received abbreviated new drug application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for its generic version of Sodium Acetate Injection 2MEQ/mL. Milla Pharmaceuticals was previously...
